Blue Trust Inc. Has $141,000 Stake in Bruker Co. (NASDAQ:BRKR)

Blue Trust Inc. increased its holdings in shares of Bruker Co. (NASDAQ:BRKRFree Report) by 14.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,914 shares of the medical research company’s stock after purchasing an additional 237 shares during the quarter. Blue Trust Inc.’s holdings in Bruker were worth $141,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Pacer Advisors Inc. raised its position in Bruker by 68.3% during the fourth quarter. Pacer Advisors Inc. now owns 13,940 shares of the medical research company’s stock worth $1,024,000 after acquiring an additional 5,656 shares in the last quarter. Portside Wealth Group LLC raised its position in shares of Bruker by 7.0% in the fourth quarter. Portside Wealth Group LLC now owns 4,178 shares of the medical research company’s stock valued at $307,000 after purchasing an additional 272 shares during the period. SG Americas Securities LLC raised its position in shares of Bruker by 30.9% in the fourth quarter. SG Americas Securities LLC now owns 28,184 shares of the medical research company’s stock valued at $2,071,000 after purchasing an additional 6,647 shares during the period. OneAscent Financial Services LLC bought a new position in shares of Bruker in the fourth quarter valued at about $226,000. Finally, Baker Tilly Wealth Management LLC raised its position in shares of Bruker by 3.0% in the fourth quarter. Baker Tilly Wealth Management LLC now owns 5,285 shares of the medical research company’s stock valued at $388,000 after purchasing an additional 156 shares during the period. Institutional investors and hedge funds own 79.52% of the company’s stock.

Insiders Place Their Bets

In other Bruker news, Director Hermann Fritz Requardt sold 15,000 shares of the stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $90.06, for a total transaction of $1,350,900.00. Following the sale, the director now directly owns 23,147 shares in the company, valued at $2,084,618.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 28.20% of the company’s stock.

Bruker Price Performance

NASDAQ:BRKR opened at $90.91 on Wednesday. The firm has a market cap of $12.52 billion, a price-to-earnings ratio of 31.13, a P/E/G ratio of 2.38 and a beta of 1.17. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.99 and a current ratio of 1.80. Bruker Co. has a 52 week low of $53.79 and a 52 week high of $94.86. The firm’s 50-day simple moving average is $83.96 and its 200 day simple moving average is $71.95.

Bruker (NASDAQ:BRKRGet Free Report) last announced its quarterly earnings data on Tuesday, February 13th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. The firm had revenue of $844.50 million for the quarter, compared to the consensus estimate of $809.35 million. Bruker had a net margin of 14.41% and a return on equity of 29.94%. The business’s revenue for the quarter was up 19.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.74 earnings per share. As a group, sell-side analysts predict that Bruker Co. will post 2.74 earnings per share for the current year.

Bruker Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 15th. Shareholders of record on Friday, March 1st were paid a dividend of $0.05 per share. The ex-dividend date was Thursday, February 29th. This represents a $0.20 dividend on an annualized basis and a yield of 0.22%. Bruker’s payout ratio is 6.85%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on BRKR. Stifel Nicolaus increased their price objective on shares of Bruker from $63.00 to $81.00 and gave the company a “hold” rating in a research report on Wednesday, February 14th. JPMorgan Chase & Co. raised shares of Bruker from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $60.00 to $90.00 in a research report on Wednesday, February 14th. Wells Fargo & Company started coverage on shares of Bruker in a research report on Tuesday, December 19th. They issued an “equal weight” rating and a $72.00 price objective on the stock. UBS Group raised their price target on shares of Bruker from $94.00 to $102.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Finally, Citigroup raised their price target on shares of Bruker from $80.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, February 14th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $84.29.

Check Out Our Latest Stock Analysis on Bruker

Bruker Profile

(Free Report)

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

See Also

Institutional Ownership by Quarter for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.